参考文献/References:
[1]. Mannheimer C, Camici P, Chester MR, et al.The problem of chronic refractory angina; report from the ESC joint study group on the treatment of refractory angina[J]. Eur Heart J,2002,23(5):355-370.
[2]. McGillion M, Arthur HM, Cook A, et al.Management of patients with refractory angina: canadian cardiovascular society/canadian pain society joint guidelines[J]. Can J Cardiol,2012,28(2 Suppl):S20-41.
[3]. Povsic TJ, Broderick S, Anstrom KJ, et al.Predictors of long-term clinical endpoints in patients with refractory angina[J]. J Am Heart Assoc,2015, 4(2):e001287-e001287.
[4]. Niccoli G, Montone RA, Lanza GA, et al.Angina after percutaneous coronary intervention: the need for precision medicine[J].Int J Cardiol,2017,248:14-19.
[5]. Serruys PW.Assessing percutaneous intervention: re-appraising the significance of residual angina[J].EuroIntervention,2015,10(11):1253-1253.
[6]. Williams B, Menon M, Satran D, et al.Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality[J]. Catheter Cardiovasc Interv,2010,75(6):886-891.
[7]. Sainsbury PA, Fisher M, de Silva R.Alternative interventions for refractory angina[J]. Heart,2017,103(23):1911-1922.
[8]. Henry TD, Satran D, Jolicoeur EM.Treatment of refractory angina in patients not suitable for revascularization[J].Nat Rev Cardiol,2014,11(2):78-95.
[9]. Konigstein M, Giannini F, Banai S.The Reducer device in patients with angina pectoris: mechanisms, indications, and perspectives[J].Eur Heart J,2018,39(11): 925-933.
[10]. Ido A, Hasebe N, Matsuhashi H, et al.Coronary sinus occlusion enhances coronary collateral flow and reduces subendocardial ischemia[J].Am J Physiol Heart Circ Physiol,2001,280(3):H1361-1367.
[11]. Paz Y, Shinfeld A.Letter to editor. Re: “Interventional treatment of pain in refractory angina. A review” by Milos Dobias et al[J].Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2014,158(3):486-487.
[12]. Banai S, Ben Muvhar S, Parikh KH, et al.Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study[J].J Am Coll Cardiol,2007, 49(17):1783-1789.
[13]. Parikh KH, Parikh P, Shah D, et al.The coronary sinus reducer: clinical evidence and technical aspects Coronary sinus reducer retains patency and efficacy at twelve years: a first in man prospective cardiac CT angiography outcome study[J].J Am Coll Cardiol,2018,71(11):261-261.
[14]. Verheye S, Jolic?ur EM, Behan MW, et al. Efficacy of a device to narrow the coronary sinus in refractory angina[J].N Engl J Med,2015,372(6):519-527.
[15]. Crea F, Camici PG, Bairey Merz CN.Coronary microvascular dysfunction: an update[J].Eur Heart J,2014,35(17):1101-1111.
[16]. Giannini F, Baldetti L, Ielasi A, et al.First experience with the coronary sinus reducer system for the management of refractory angina in patients without obstructive coronary artery disease[J].JACC Cardiovasc Interv,2017,10(18): 1901-1903.
[17]. Giannini F, Baldetti L, Konigstein M, et al.Safety and efficacy of the reducer: a multi-center clinical registry - REDUCE study[J]. Int J Cardiol,2018,269:40-44.
[18]. Ponticelli F, Tzanis G, Gallone G, et al.Safety and efficacy of Coronary Sinus Reducer implantation at 2-year follow-up[J].Int J Cardiol,2019, 292:87-90.
[19]. Baldetti L, Colombo A, Banai S, et al.Coronary sinus reducer non-responders: insights and perspectives[J].EuroIntervention,2018,13(14):1667-1669.
[20]. Zivelonghi C, Vermeersch G, Verheye S, et al.Incomplete coronary sinus reducer endothelialization as potential mechanism of clinical failure[J].Catheter Cardiovasc Interv,2019,94(1):120-122.
[21]. Tzanis G, Durante A, Mitomo S, et al.Percutaneous management of periprocedural coronary sinus reducer migration[J].Catheter Cardiovasc Interv, 2019, 93(4): E235-E237.
[22]. Cortese B, di Palma G, Latini R.Coronary sinus perforation during reducer implantation[J].Catheter Cardiovasc Interv,2018,91(7):1291-1293.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(9):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(9):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(9):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(9):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(9):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(9):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(9):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(9):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(9):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(9):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]